Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C6H5O4S.Zn |
Molecular Weight | 411.742 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].OC1=CC=C(C=C1)S([O-])(=O)=O.OC2=CC=C(C=C2)S([O-])(=O)=O
InChI
InChIKey=ZNVKGUVDRSSWHV-UHFFFAOYSA-L
InChI=1S/2C6H6O4S.Zn/c2*7-5-1-3-6(4-2-5)11(8,9)10;/h2*1-4,7H,(H,8,9,10);/q;;+2/p-2
DescriptionSources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459Curator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including
http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity
Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2307275https://www.ncbi.nlm.nih.gov/pubmed/10721938http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicityhttps://www.ncbi.nlm.nih.gov/pubmed/25374537 | https://www.ncbi.nlm.nih.gov/pubmed/15639165
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.
Originator
Sources: https://www.webelements.com/zinc/history.htmlhttp://www.drugdevelopment-technology.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/http://sciencing.com/uses-zinc-carbonate-7889200.html
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612426 |
|||
Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783 |
|||
Target ID: CHEMBL2364710 |
|||
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194 |
|||
Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | CORTROPHIN-ZINC Approved UseTreatment of ulcerative colitis and other colonic disorders. Launch Date1955 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Secondary | VORAXAZE Approved UseIndicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date2012 |
|||
Primary | VUSION Approved UseINDICATIONS AND USAGE
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when
complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or
budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal
culture for Candida albicans is not adequate evidence of candidal infection since colonization
with C. albicans can result in a positive culture. The presence of candidal infection should be
established by microscopic evaluation prior to initiating treatment.
VUSION Ointment should be used as part of a treatment regimen that includes measures
directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and
frequent diaper changes. Launch Date2006 |
|||
Primary | ZINC OXIDE Approved UseUnknown |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date1987 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date1987 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date1987 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
A medicated polycarboxylate cement to prevent complications in composite resin therapy. | 1990 Jan |
|
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates. | 1993 Aug |
|
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. | 1997 Feb |
|
Thujaplicin-copper chelates inhibit replication of human influenza viruses. | 1998 Aug |
|
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study. | 1999 May |
|
Inhibition of HIV-1 infection by zinc group metal compounds. | 1999 Sep |
|
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats. | 2000 Sep |
|
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. | 2002 Mar 1 |
|
Impact of the mother's zinc deficiency on the woman's and newborn's health status. | 2005 |
|
Erythrocyte zinc content in critically ill patients. | 2005 |
|
Zinc in attention-deficit/hyperactivity disorder. | 2005 Aug |
|
Effects of zinc supplementation in patients with type 1 diabetes. | 2005 Summer |
|
Characterization and inhibition of SARS-coronavirus main protease. | 2006 |
|
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs. | 2006 Dec |
|
Effect of end-stage renal disease and diabetes on zinc and copper status. | 2006 Jul |
|
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality. | 2006 May |
|
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells. | 2009 Mar 28 |
|
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing. | 2010 Dec |
|
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity. | 2010 Dec |
|
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. | 2010 Feb |
|
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells. | 2010 Jan 12 |
|
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells. | 2010 Jul |
|
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
|
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells. | 2011 Jul |
|
Zinc induces chemokine and inflammatory cytokine release from human promonocytes. | 2011 Nov 30 |
|
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study. | 2011 Sep |
|
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. | 2012 Feb |
|
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells. | 2013 Mar |
|
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line. | 2014 Mar 3 |
|
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. | 2014 May 16 |
|
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice. | 2014 Nov 4 |
|
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction. | 2015 Sep |
|
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents. | 2016 Oct 1 |
|
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers. | 2016 Sep |
|
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass. | 2017 May 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26892107
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6583216
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
89002
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C84250
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
4O71YT5YB5
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
100000127775
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
204-867-8
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
DTXSID1059571
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
2551
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
4O71YT5YB5
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
SUB33888
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
89831
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
127-82-2
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
31391
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | |||
|
m11620
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
51136-97-1
Created by
admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
ACTIVE MOIETY
SUBSTANCE RECORD